Non-small Cell Lung Cancer
A Study of the Combination of Necitumumab (LY3012211) and Pembrolizumab (MK3475) in Participants With NSCLC
The main purpose of this study is to evaluate the safety and efficacy of the combination of necitumumab with pembrolizumab in participants with stage IV NSCLC.
The results of this study are not yet available.
The duration of your participation will depend on the duration of your study treatment, your disease progression, and follow-up visits
Here you can find out a bit more about the requirements for volunteers who took part in this study
Participant must have stage IV Non-Small Cell Lung Cancer
Participant must have progressed after 1 platinum-based chemotherapy regimen. Participant whose tumor has an EGFR activating mutation or ALK translocations must have prior treatment with epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor and anaplastic lymphoma kinase (ALK) inhibitors
Participant must have tumor tissue available for biomarker analyses
Participant must not have surgery within 30 days of study start
Participant must not have had prior treatment with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, or anti-cytotoxic T lymphocyte-associated antigen-4 antibody or EGFR-directed monoclonal antibody (mAb)
Participant must not have undergone chest irradiation within 4 weeks prior to receiving study treatment
Participant must not be currently enrolled in a clinical trial involving an investigational product or non-approved use of a drug or device
Participant must not be pregnant or breastfeeding